Diagnosis and Management of GYn/Ob Manifestation of Systemic Lupus Erythematosus

Abstract

Systemic lupus erythematosus (SLE), being an autoimmune disease with multisystem manifestations, poses significant challenges for women of reproductive age since infertility and increased risk of fetus loss reduce reproductive capacity. Furthermore, SLE seems to be associated with higher cancer probabilities of vulvar and vaginal cancers, as well as non-Hodgkin lymphoma (NHL) and lung cancer. Conversely, evidence suggests that ovarian and uterine cancers may exhibit a protective association with SLE. Through a review of current literature, we aim to elucidate the gynecological and obstetric manifestations and risks of SLE while proposing preventive and therapeutic strategies for this vulnerable patient population. Regarding cancer prevention, it is imperative to encourage SLE patients to undergo regular cancer screenings, consider human papilloma virus (HPV) vaccination, and adopt lifestyle modifications to mitigate known cancer risk factors such as smoking and obesity. During pregnancy, successful management entails meticulous planning and tailored medication strategies to minimize risks for both mother and fetus and mitigate the heightened risk of disease flare-ups typically associated with pregnancy. This comprehensive approach seeks to lessen the impact of cancer on SLE patients and enhance overall health outcomes. In general, we investigate the impact of SLE on the reproductive health of patients and the significant risk of malignant diseases later in woman’s life.